On August 28, 2020, the phase I clinical trial of the recombinant protein COVID-19 vaccine (Sf9 cell) of West China Hospital, Sichuan University kicked off its training effort in China Medical City (in Taizhou, Jiangsu Province), and the clinical trial of the vaccine will be carried out by Zhu Fengcai, Director of Jiangsu Provincial Center for Disease Control and Prevention (CDC) and his team.

At 9:00 a.m on August 29, the first vaccine is injected in a volunteer.

According to Wei Yuquan, an academician and Director of the State Key Laboratory of Biotherapy at West China Hospital, Sichuan University, the recombinant protein COVID-19 vaccine was approved for clinical trials by the National Medical Products Administration on August 21. The vaccine was produced by inserting the genes of COVID-19 virus into insect cells, which means the cells can be used to produce high-quality recombinant vaccine proteins and purify them for refinement. Such an approach is suitable for large-scale manufacturing and marketing of vaccines. The scientific results were published in the internationally renowned journal Nature on July 29. So far, all subjects felt good and had no adverse reactions.